What side effects does the Mounjaro injection cause?

Which side effects are most people actually reporting?

The majority of people using the Mounjaro injection experience at least one gastrointestinal side effect at some point during treatment. Nausea sits at the top of the list, followed by diarrhoea, constipation, vomiting, reflux, and burping. Fatigue, headache, and dizziness appear less often but are documented in the trial data and on the NHS tirzepatide medicines page.

The pattern is fairly consistent: symptoms are worst in the first few days after starting or increasing a dose, then fade as the body adjusts. By the time the next pen begins, most people are comfortable at that level. That graduated schedule (starting at 2.5mg and moving up only when a prescriber confirms readiness) exists precisely because it softens this effect.

A question our prescribers hear most weeks is whether the nausea means something has gone wrong. Usually it does not. Eating smaller portions, slowing down at meals, keeping hydrated, and avoiding rich or fatty foods in the first days of a new dose can all reduce intensity. Anyone finding the gastrointestinal effects genuinely unmanageable should speak to their prescriber rather than simply stopping, because the right move (pausing the titration, staying at the current dose) depends on the clinical picture. Our guide to nausea on Mounjaro goes into practical detail on managing this.

Injection-site reactions (redness, bruising, mild swelling) are also common and almost always resolve on their own. Rotating the site between the abdomen, thigh, and upper arm at each weekly dose helps.

What are the serious side effects that need urgent medical attention?

Serious effects are uncommon, but knowing the warning signs matters more than the statistics. In January 2026, the MHRA issued a Drug Safety Update for GLP-1 medicines specifically flagging acute pancreatitis: severe, persistent stomach pain that spreads to the back, with or without vomiting. If that happens, stop the injection and get urgent medical help the same day. Do not wait to see if it passes.

Other situations that need prompt attention include signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing, rapid heartbeat), gallbladder symptoms (sharp upper-right abdominal pain, especially after eating), and any signs of significant dehydration following severe vomiting or diarrhoea (very dark urine, dizziness on standing, inability to keep fluids down).

People with type 2 diabetes who are also taking insulin or a sulphonylurea face an additional consideration: tirzepatide can lower blood sugar, and the combination raises the risk of hypoglycaemia. If you are on both, your prescriber will review the doses. Sudden changes in vision should also prompt same-day contact with a clinician, particularly for anyone with known diabetic retinopathy.

Low mood or thoughts of self-harm have been noted in the broader GLP-1 literature. These are not confirmed as a causal effect of tirzepatide specifically, but they are worth knowing about: tell a prescriber or GP straight away if mood changes feel significant. The full side-effect reference page details this and other less common effects.

Are some people more likely to have side effects than others?

Individual variation is real. Some people move through the entire dose schedule with nothing beyond mild, brief nausea. Others find each step up noticeably uncomfortable for a week or two. There is no reliable way to predict this in advance, which is one reason the graduated schedule exists rather than a fixed starting dose.

Certain factors do appear in the clinical data. People who have a history of frequent nausea or motion sickness seem to find the gastrointestinal effects more pronounced. Starting a dose during a period of illness or stress can make symptoms feel worse. The 5mg dose level tends to produce more noticeable GI effects than the earlier 2.5mg pen for many people, simply because 2.5mg is a tolerability dose whose job is system adjustment, not yet full therapeutic effect.

People with a history of pancreatitis, certain gallbladder conditions, or severe gastrointestinal disease need to discuss these with a prescriber before starting, as tirzepatide may not be appropriate. The same applies to anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Our page on why some people experience fewer side effects looks at the individual factors in more detail, and our 5mg side-effect guide covers what to expect at that specific dose step.

How should side effects be reported, and what does the Black Triangle mean?

Tirzepatide carries a Black Triangle (▼) designation, which means the MHRA is collecting additional safety data beyond what was gathered in pre-approval trials. It does not mean the medicine is less safe than one without the symbol; it means the regulator wants a richer, real-world picture. That picture is built from reports submitted by patients and clinicians through the Yellow Card scheme.

If you experience any side effect that concerns you, reporting it takes about ten minutes and genuinely contributes to the ongoing safety review of this medicine in UK clinical practice. You can report suspected side effects whether or not you think they are definitively caused by the injection.

At nume, every repeat order goes through a fresh clinical review, not a checkbox exercise. If side effects have changed between orders, that is flagged. Anyone with questions between orders can reach the team through our contact page; aftercare is available seven days a week. If you are weighing up whether the side-effect profile of Mounjaro fits your situation, speak to our prescribers as part of a free consultation, suitability, history, and concerns are all discussed before any prescription is issued.